The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Sulfonamides: a patent review (2008 – 2012)
Open accessAbstract
INTRODUCTION: The primary sulfonamide moiety is present in many clinically used drugs, such as diuretics (furosemide, indapamide, chlorthalidone, thiazides); carbonic anhydrase (CA) inhibitors (CAIs) (including acetazolamide, dichlorophenamide, dorzolamide and brinzolamide); antiepileptics (zonisamide and sulthiame); the antipsychotic sulpiride and the cycloxygenase 2 (COX2) inhibitors celecoxib and valdecoxib. Recently, novel drugs have been launched, such as apricoxib and pazopanib, which also incorporate this group. AREAS COVERED: The article presents the main classes of sulfonamides investigated between 2008 and 2012. Specifically, the authors review the scientific and patent literature on CAIs, COX2 inhibitors, pazopanib and its congeners, which are multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit. EXPERT OPINION: Most patents deal with sulfonamide CAIs incorporating NO-donating moieties as antiglaucoma agents, or with compounds targeting the tumor-associated isoforms CA IX/XII. The antidandruff actions of sulphonamides, which inhibit yeast CAs, were also claimed. Apricoxib (a COX2 inhibitor) and pazopanib, a tyrosine kinase inhibitor, show significant antitumor activity and several patents deal with these drugs. There is a constant need of novel sulfonamides to act as selective antiglaucoma drugs (targeting CA II), as antitumor agents/diagnostic tools (targeting CA IX/XII), and to treat and diagnose other disease. This privileged structural motif is likely to be present in other drugs in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH
Švastová, E., Hulı́ková, A., Rafajová, M., Zat'ovičová, M., Gibadulinová, A., Casini, A., Cecchi, A., Scozzafava, A., Supuran, C. T., Pastorek, J., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.043 · Cited by 711
Self-citation
Cited by
Structure and function of carbonic anhydrases
Supuran, C. T. (2016) · Biochemical Journal · doi:10.1042/bcj20160115 · Cited by 922
Self-citationBagal, D. B., Kachkovskyi, G., Knorn, M., Rawner, T., Bhanage, B. M., & Reiser, O. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501880 · Cited by 361
Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013)
Monti, S. M., Supuran, C. T., & De Simone, G. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.798648 · Cited by 265
Self-citation
Metadata
- Authors
- Carta, F., Scozzafava, A., & Supuran, C. T.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2012-06-15
- Volume
- 22
- Issue
- 7
- Pages
- 747-758
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2019982783
- Cited by
- 234
- References
- 1
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulfonamides: a patent review (2008 – 2012). https://app.cochat.ai/papers/10.1517/13543776.2012.698264
- The paper
- Carta, F., Scozzafava, A., & Supuran, C. T. (2012). Sulfonamides: a patent review (2008 – 2012). Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2012.698264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.